Back your fave M&As in Merger Madness

For the irrepressible matchmakers among you, we offer the Wall Street Journal Health Blog's annual March Madness bracket, pharma-style. This time, the subject is--yes--M&A. The blogsters have paired the engaged couples--Pfizer/Wyeth, Roche/Genentech, Eli Lilly/ImClone, Merck/Schering-Plough--and put together the wallflowers, too. So Johnson & Johnson is bracketed with Amgen, Sanofi-Aventis with Bristol-Myers Squibb, et al. Check it out. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.